CosmeRNA ARI European Trial Update: Topical SAMiRNA Androgen Receptor Silencing Achieves Significant Terminal Hair Density Increase and Reduced Shedding in 6-Month RCT

Powered by a novel self-assembled micelle siRNA technology (SAMiRNA-AR68), this treatment selectively “dials down” androgen receptors directly inside hair follicle cells. Because it degrades the genetic blueprint for androgen receptors locally on the scalp rather than altering circulating hormones, it provides a safe, non-hormonal, once-weekly alternative to daily pills and lotions.

What Is It and How Does It Work?

CosmeRNA ARI is a topical hair tonic designed to be applied to the scalp just once a week or twice a month.

It works through a cutting-edge process called Topical SAMiRNA-Mediated Androgen Receptor Silencing:

1. The Root Cause: In pattern hair loss, dihydrotestosterone (DHT) binds to androgen receptors (AR) inside the scalp’s dermal papilla cells, triggering inflammation that slowly shrinks the hair follicles. Traditional oral medications attempt to lower DHT throughout the entire body, which can lead to systemic hormonal side effects.

2. Micelle Nanoparticle Delivery: SAMiRNA stands for Self-Assembled Micelle inhibitory RNA. The active siRNA molecule is engineered to assemble into microscopic lipid spheres (micelles). These nanostructures allow the treatment to easily penetrate the scalp’s outer skin barrier and concentrate inside hair follicle cells.

3. Selective Receptor Degradation: Once inside the cell, the siRNA recruits the cell’s natural RNA interference machinery to destroy messenger RNA (mRNA) carrying the instructions for building androgen receptors. By significantly reducing the number of available receptors, DHT cannot attach to the follicle, effectively protecting the root from shrinking without changing hormone levels in the bloodstream.

The Science: Significant Terminal Density Gains in European Study

The double-blind, randomized, placebo-controlled trial evaluated adult men and women in Germany over a 6-month treatment period to confirm the efficacy and safety of the SAMiRNA-AR68 formulation.

Key findings from the published trial include:

• Increased Terminal Hair Density: Participants using the CosmeRNA ARI tonic experienced a statistically significant increase in terminal (thick, pigmented) hair density by Week 24 compared to the placebo group.

• Marked Reduction in Shedding: Phototrichogram imaging and hair collection analysis confirmed a clear reduction in daily hair shedding among participants in the treatment arm compared to baseline.

• High Dermatological Safety: Clinical skin evaluations (including Dermatest 5-star safety testing) confirmed zero pathological skin lesions, zero systemic hormonal complications, and no inflammatory cytokine responses.

• Convenient Weekly Dosing: Unlike standard topical treatments that require daily application, CosmeRNA ARI maintained its hair density gains with just once-weekly or twice-monthly applications, vastly improving long-term patient compliance.

“CosmeRNA ARI demonstrated that AGA patients in Germany improve AGA without side effects… showing a reduction in shed hair count, an increase in hair density, and confirming its safety profile.” — Study Researchers, Clinical & Experimental Dermatology and Therapies.

When Will It Be Available?

• Current Availability: CosmeRNA ARI is currently available as a specialized cosmetic hair tonic in Western Europe (EU) and the United Kingdom via CPNP and SCPN regulatory notification pathways.

  Read next

  Whats the best shampoo for hair loss?

• Global Expansion: Following the publication of this 6-month European RCT, the manufacturer (Bioneer) is expanding commercial distribution across additional international markets.

How you can benefit from this treatment now

If you are looking for a non-hormonal hair treatment that eliminates the hassle of daily applications, CosmeRNA ARI offers actionable avenues today:

1. Access in Covered Regions: Residents in the European Union and the UK can purchase CosmeRNA ARI directly through authorized cosmetic stockists without needing a medical prescription.

2. Ideal for Patients Sensitive to Anti-Androgens: Because SAMiRNA silences local androgen receptors rather than suppressing systemic DHT or testosterone levels, it provides an alternative for individuals who have experienced side effects from oral 5$\alpha$-reductase inhibitors.

3. Combine with Growth Stimulants: Because CosmeRNA ARI operates via receptor silencing rather than vasodilation, it can be safely integrated alongside blood-flow stimulants (such as minoxidil or Low-Level Laser Therapy) under the guidance of a hair specialist.

Sources:

• Efficacy of CosmeRNA ARI in Improving Androgenetic Alopecia in Europeans: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial over 6 months, Clinical & Experimental Dermatology and Therapies, 2025

  [cite: 1, 2]

• SAMiRNA-AR68 Mechanism of Action and Clinical Evidence in Androgenetic Alopecia, EMJ Dermatology / CosmeRNA Insights, February 2026

  [cite: 2, 4, 6]